Literature DB >> 21505983

Effects of Panax notoginoside on the expression of TGF-β1 and Smad-7 in renal tissues of diabetic rats.

Qingnian Tu1, Juan Qin1, Hui Dong2, Fuer Lu3, Wei Guan1.   

Abstract

In order to explore the effects of Panax notoginoside (PNS) on the expression of transforming growth factor β1 (TGF-β1) and Smad-7 in renal tissues of diabetes, a rat model of diabetic nephropathy was set up by intravenous injection of streptozotocin (STZ). Wistar rats were randomly divided into normal group, diabetic control group, group treated by PNS at low-dosage (PL), group treated by PNS at high-dosage (PH) and group treated by catopril (C), respectively. Fasting blood glucose (FBG), renal index, endogenous creatinine clearance rate (C(Cr)) and urinary albumin (UAlb) in 24 h were examined after 6 weeks. Meanwhile, the expressions of TGF-β1 and Smad7 in renal tissues were immunohistochemically dectected. At the end of the sixth week, FBG, renal index, C(cr), UAlb were all elevated significantly in control group (P<0.01). The expression of TGF-β1 protein was increased while Smad7 protein decreased in renal tissue (P<0.01). However, the treatment with PNS reversed the aforementioned changes in renal tissues of diabetic rats. These results indicate that PNS possess a protective effect on the kidney of diabetic rats and it might protect kidney by inhibiting the expression of TGF-β1 protein and enhancing the expression of Smad7 protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505983     DOI: 10.1007/s11596-011-0250-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  14 in total

1.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation.

Authors:  P Kavsak; R K Rasmussen; C G Causing; S Bonni; H Zhu; G H Thomsen; J L Wrana
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

Review 2.  Pathogenesis of diabetic nephropathy.

Authors:  A E Raptis; G Viberti
Journal:  Exp Clin Endocrinol Diabetes       Date:  2001       Impact factor: 2.949

3.  Effects of Panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus.

Authors:  Qing-nian Tu; Hui Dong; Fu-er Lu
Journal:  Chin J Integr Med       Date:  2011-08-09       Impact factor: 1.978

4.  Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor.

Authors:  Yuko Okazaki; Yasushi Yamasaki; Haruhito A Uchida; Kazunori Okamoto; Minoru Satoh; Keisuke Maruyama; Yohei Maeshima; Hitoshi Sugiyama; Takeshi Sugaya; Naoki Kashihara; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

Review 5.  Transforming growth factor-beta and Smad signalling in kidney diseases.

Authors:  Wansheng Wang; Vijay Koka; Hui Y Lan
Journal:  Nephrology (Carlton)       Date:  2005-02       Impact factor: 2.506

6.  Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice.

Authors:  Zhong-Hua Chen; Jie Li; Jie Liu; Yuan Zhao; Pu Zhang; Meng-Xue Zhang; Liu Zhang
Journal:  Am J Chin Med       Date:  2008       Impact factor: 4.667

Review 7.  TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy.

Authors:  Claire E Hills; Paul E Squires
Journal:  Am J Nephrol       Date:  2009-11-04       Impact factor: 3.754

Review 8.  The pathogenesis of diabetic nephropathy.

Authors:  Suma Dronavalli; Irena Duka; George L Bakris
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-07-08

Review 9.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

10.  Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

Authors:  N J Laping; E Grygielko; A Mathur; S Butter; J Bomberger; C Tweed; W Martin; J Fornwald; R Lehr; J Harling; L Gaster; J F Callahan; B A Olson
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  7 in total

1.  Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats.

Authors:  Yue-Guang Du; Li-Pei Wang; Jun-Wen Qian; Ke-Na Zhang; Ke-Fu Chai
Journal:  Chin J Integr Med       Date:  2015-12-28       Impact factor: 1.978

2.  EFFECTS OF GINSENG AND ITS FOUR PURIFED GINSENOSIDES (Rb2, Re, Rg1, Rd) ON HUMAN PANCREATIC ISLET β CELL IN VITRO.

Authors:  John Z Q Luo; Joseph W Kim; LuGuang Luo
Journal:  Eur J Pharm Med Res       Date:  2016-01

Review 3.  Ancient records and modern research on the mechanisms of chinese herbal medicines in the treatment of diabetes mellitus.

Authors:  Hai-Ming Zhang; Feng-Xia Liang; Rui Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-01       Impact factor: 2.629

4.  Chinese medicines in the treatment of experimental diabetic nephropathy.

Authors:  Jing-Yi Liu; Xiao-Xin Chen; Sydney Chi-Wai Tang; Stephen Cho-Wing Sze; Yi-Bin Feng; Kai-Fai Lee; Kalin Yan-Bo Zhang
Journal:  Chin Med       Date:  2016-02-24       Impact factor: 5.455

5.  Analysis of the Renal Protection and Antioxidative Stress Effects of Panax notoginseng Saponins in Diabetic Nephropathy Mice.

Authors:  Wei Mi; Min Yu; Shuying Yin; Yuhan Ji; Tala Shi; Ning Li
Journal:  J Immunol Res       Date:  2022-10-05       Impact factor: 4.493

6.  Ginseng and diabetes: the evidences from in vitro, animal and human studies.

Authors:  Hai-Dan Yuan; Jung Tae Kim; Sung Hoon Kim; Sung Hyun Chung
Journal:  J Ginseng Res       Date:  2012-01       Impact factor: 6.060

Review 7.  Review of Herbal Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy.

Authors:  Guang-dong Sun; Chao-yuan Li; Wen-peng Cui; Qiao-yan Guo; Chang-qing Dong; Hong-bin Zou; Shu-jun Liu; Wen-peng Dong; Li-ning Miao
Journal:  J Diabetes Res       Date:  2015-11-15       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.